TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1800394
Drug: Nifedipine in
Normalized name: nifedipine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine in combination with dilazep (50 mg three times a day)
Study: 1800394
Drug: Nifedipine alone
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine alone and in combination with dilazep
Study: 6401172
Drug: NTG spray
Normalized name: nitroglycerin Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG spray 0.8 mg
Study: 15811205
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (TLA and TIM)
Study: 11222785
Drug: IVIg (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (1 g/kg)
Study: 9429051
Drug: Perphenazine 70
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perphenazine 70 micrograms.kg‐1 up to 5 mg
Study: 8508192
Drug: 2.5‐mg boron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5‐mg boron supplement
Study: 3543767
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg, four times daily for six weeks, initiated during the third trimester)
Study: 3543767
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four times daily for six weeks)
Study: 3543767
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg, four times daily for six weeks, initiated during the second trimester)
Study: 3543767
Drug: Clindamycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (150 mg, four times daily for six weeks)
Study: 21472661
Drug: PF-734200 2
Normalized name: chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-734200 2 mg
Study: 21472661
Drug: PF-734200 5
Normalized name: haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-734200 5 mg
Study: 21472661
Drug: PF-734200 10
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-734200 10 mg
Study: 21472661
Drug: PF-734200 20
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-734200 20 mg
Study: 18784341
Drug: gD2 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD2 DNA vaccine (100 microg, 300 microg, 1,000 microg, or 3,000 microg)
Study: 18784341
Drug: gD2 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD2 DNA vaccine (3,000 microg)
Study: 14634493
Drug: Ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 16 microg/kg twice daily
Study: 30402880
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of M281 (anti-FcRn antibody) at doses of 15 or 30 mg/kg
Study: 30402880
Drug: M281 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: M281 (all doses)
Study: 22289752
Drug: Anti-neutrophil cytoplasmic
Normalized name: Anti-neutrophil cytoplasmic antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-neutrophil cytoplasmic antibody (ANCA) in the acute phase of Kawasaki disease
Study: 22289752
Drug: Anti-neutrophil cytoplasmic
Normalized name: Anti-neutrophil cytoplasmic antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-neutrophil cytoplasmic antibody (ANCA) in the recovery phase of Kawasaki disease
Study: 22289752
Drug: Anti-neutrophil cytoplasmic
Normalized name: Anti-neutrophil cytoplasmic antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-neutrophil cytoplasmic antibody (ANCA) status in Kawasaki disease
Study: 18198650
Drug: Qiangyue Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiangyue Cream (QYC)
Study: 18198650
Drug: Halometasone cream
Normalized name: halometasone
DrugBank: Halometasone (DB13728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halometasone cream
Study: 2212452
Drug: Imidazole salicylate
Normalized name: imidazole salicylate
DrugBank: Imidazole salicylate (DB13860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidazole salicylate 750 mg three times daily
Study: 20637539
Drug: PSA >
Normalized name: Prostate-Specific Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA > or = 3.0 ng/ml
Study: 17761004
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving inactive ultrasound and gentle application of an inert gel over the shoulder region.
Study: 8073240
Drug: Pharmaceutical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical treatments
Study: 2799271
Drug: Ferric-aluminum-fluoride solution
Normalized name: aluminum fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric-aluminum-fluoride solution (FeAlF)
Study: 1107648
Drug: Ocusert drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocusert drug delivery system
Study: 31090673
Drug: Acute aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute aspirin (81 mg; single-dose)
Study: 31090673
Drug: Chronic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic aspirin (81 mg; 14 days)
Study: 25650370
Drug: Perhexiline 200
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perhexiline 200 mg for 1 month
Study: 10830255
Drug: Home oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home oxygen therapy
Study: 19382032
Drug: 5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/day peroral iron for 2 months
Study: 17998507
Drug: Ranibizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (both doses)
Study: 28303471
Drug: Neutral pH
Normalized name: Gelato Neutral pH 2 % Oral Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral pH bleaching gel (Pola Office+)
Study: 28303471
Drug: Acid pH
Normalized name: Acid phosphatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid pH bleaching gel (Pola Office)
Study: 24149738
Drug: 300 mg·d(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg·d(‐1) magnesium oxide supplementation
Study: 17908741
Drug: Combined vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vitamin A and zinc supplement
Study: 14726116
Drug: Controlled Release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled Release (CR) tablets
Study: 14726116
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) tablets
Study: 11331213
Drug: l‐T4 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐T4 administration (100 microg/day)
Study: 9330779
Drug: BMS‐181101 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐181101 administered with food
Study: 9330779
Drug: BMS‐181101 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐181101 administered without food
Study: 7970996
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg intravenous allopurinol
Study: 7970996
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg intravenous allopurinol
Study: 2912911
Drug: Treatment density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment density (repeating photocoagulation)
Study: 238810
Drug: Loxapine succinate
Normalized name: Loxapine Succinate
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loxapine succinate (LOX) 40-65 mg/day, b.i.d. schedule
Study: 238810
Drug: Trifluoperazine hydrochloride
Normalized name: Trifluoperazine Hydrochloride
DrugBank: Trifluoperazine (DB00831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trifluoperazine hydrochloride (TFP) appropriate dosage
Study: 28300867
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg bid
Study: 24090384
Drug: Magnesium orotate
Normalized name: Magnesium orotate
DrugBank: Magnesium orotate (DB13786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium orotate and other antihypertensive, metabolic drugs, sedative and uroseptic phytotherapy, and nondrug measures
Study: 17144787
Drug: Complementary medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary medicine (including acupuncture, aromatherapy, massage, homeopathy, meditation, reflexology, herbal medicine, yoga, dietary supplements, relaxation techniques)
Study: 15686716
Drug: Steroid weaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid weaning
Study: 8783703
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg b.i.d. for 5 days)
Study: 6508263
Drug: Comparative agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative agents (piperacillin or moxalactam)
Study: 28724815
Drug: Intracameral mydriatic
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral mydriatic solution
Study: 14709298
Drug: Topical mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mydriatics
Study: 22999400
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of 10mg of 0.5% hyperbaric bupivacaine combined with 80 mcg of morphine and 2.5 mcg of sufentanil
Study: 22999400
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 10mg of 0.5% hyperbaric bupivacaine combined with 80 mcg of morphine
Study: 17488312
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg/kg (Group K1)
Study: 17488312
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg/kg (Group K2)
Study: 17488312
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg/kg (Group P)
Study: 15034949
Drug: Benznidazole (BZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BZ) with Thioctic Acid (TA) at daily doses of 50 to 100 mg for 30 days
Study: 9630294
Drug: Full standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full standardized dose of laser (40 x 1500 mW for 1500 ms)
Study: 9630294
Drug: Half standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half standardized dose of laser (40 x 750 mW for 1500 ms)
Study: 9630294
Drug: Full treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full treatment subgroup with neovascular glaucoma
Study: 7983235
Drug: Nifedipine 50
Normalized name: nifedipine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 50 mg once a day
Study: 7983235
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard 20 mg twice a day
Study: 2512486
Drug: Isocaloric protein‐restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric protein‐restricted diet (0.4 g of protein per kilogram of body weight per day)
Study: 28104250
Drug: Daclizumab 150mg
Normalized name: DACLIZUMAB 150MG/ML SYR
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab 150mg subcutaneous every 4 weeks
Study: 28104250
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 30mcg intramuscular once weekly
Study: 21777736
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of fipronil, amitraz and (S)-methoprene (CERTIFECT™) at 28 days prior to tick infestation.
Study: 21777736
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of fipronil, amitraz and (S)-methoprene (CERTIFECT™) at 21 days prior to tick infestation.
Study: 21777736
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of fipronil, amitraz and (S)-methoprene (CERTIFECT™) at 14 days prior to tick infestation.
Study: 19433838
Drug: Multimodal cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cancer screening (including CA-125 tests, transvaginal sonograms, chest radiographs, flexible sigmoidoscopies, digital rectal examinations, and serum PSA tests)
Study: 11045914
Drug: Low-dose PGE1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PGE1 (2.5 - 5.0 microg)
Study: 11045914
Drug: Standard sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sex therapy for twelve weeks
Study: 8443935
Drug: Tretinoin emollient
Normalized name: Tretinoin Emollient Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin emollient cream 0.01%
Study: 1552056
Drug: Tretinoin emollient
Normalized name: Tretinoin Emollient Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin emollient cream 0.001%
Study: 3886304
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg brompheniramine maleate
Study: 3886304
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg clemastine fumarate
Study: 24354588
Drug: 13-valent conjugated
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent conjugated pneumococcal vaccine
Study: 10090927
Drug: Busulfan 16
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 16 mg/kg
Study: 7884425
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2 intravenously over 1 hour every 3 weeks)
Study: 2206058
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injections
Study: 2206058
Drug: No injections
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injections
Study: 6108392
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (2 doses of 40 micrograms)
Study: 6108392
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (3 doses of 40 micrograms)
Study: 6108392
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of Hepatitis B vaccine
Study: 28747328
Drug: Daily meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily meal replacements of 1-2 meals for 3 years
Study: 24877791
Drug: Talking about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talking about stories of difficulty (treatment)
Study: 24877791
Drug: Daily events
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily events (control)
Study: 23906400
Drug: Low-dose L-amlodipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose L-amlodipine besylate (2.5 mg/d)
Study: 23906400
Drug: High-dose L-amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose L-amlodipine besylate (5.0 mg/d)
Study: 23906400
Drug: Amlodipine maleate
Normalized name: Amlodipine Maleate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine maleate (5.0 mg/d)
Study: 19595142
Drug: T0901317, 9‐cis
Approvals — FDA: no, EMA: no, PMDA: no
Description: T0901317, 9‐cis retinoic acid, chenodeoxycholic acid (CDCA) - agonists of LXR, RXR, FXR
Study: 16563905
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg twice daily
Study: 11267622
Drug: Nicotine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (21 mg/24 h)
Study: 11267622
Drug: Nicotine (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (42 mg/24 h)
Study: 3174738
Drug: Mecamylamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (10 mg)
Study: 7860158
Drug: All strains
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All strains of measles vaccine
Study: 2680162
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day methylprednisolone for 3 days
Study: 2680162
Drug: 1,000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/day methylprednisolone for 3 days
Study: 788430
Drug: Control insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control insulin tolerance test
Study: 23234491
Drug: Ditto™ intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ditto™ intervention group (receiving Ditto™, procedural preparation and Ditto™ distraction)
Study: 10211919
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/day, flexible titration up to 200 mg/day)
Study: 2223140
Drug: Simple mastectomy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple mastectomy with postoperative x-ray treatment
Study: 2198932
Drug: Acetazolamide tablets
Normalized name: Acetazolamide Tablets
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide tablets
Study: 23862400
Drug: Intranasal sodium
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sodium hyaluronate
Study: 21209236
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg (TAD) alone
Study: 21209236
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg (TAD) with tipranavir/ritonavir (TPV/r) 500/200 mg
Study: 21209236
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg (TAD) with steady-state TPV/r
Study: 15190136
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of ondansetron
Study: 15098526
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of dolasetron
Study: 9519171
Drug: MXL capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: MXL capsules (once-daily morphine preparation)
Study: 9519171
Drug: MST Continus
Normalized name: MST Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST Continus tablets (twice-daily morphine preparation)
Study: 27862179
Drug: (S)-ketamine 10
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-ketamine 10 mg
Study: 27862179
Drug: phenytoin 300
Normalized name: phenytoin 300 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenytoin 300 mg
Study: 27862179
Drug: pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pregabalin 300 mg
Study: 27862179
Drug: fentanyl 3
Normalized name: FENTANYL 37.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 3 μg kg-1
Study: 27862179
Drug: ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 600 mg
Study: 25216597
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin therapy (EPT+) in normotensive women
Study: 25216597
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/day) in hypertensive women
Study: 25216597
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg/day) in hypertensive women
Study: 25216597
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin therapy (EPT+) with Hydrochlorothiazide in hypertensive women
Study: 25216597
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin therapy (EPT+) with Perindopril in hypertensive women
Study: 24334578
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches over semipermeable membrane dressings (SMD)
Study: 24334578
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches without semipermeable membrane dressings (SMD)
Study: 16249215
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg/m2 every 3 weeks x 4 cycles with concurrent carboplatin AUC 6 every 3 weeks x 4 cycles
Study: 16249215
Drug: Paclitaxel 75
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 75 mg/m2/week x 12 with concurrent carboplatin AUC 6 every 3 weeks x 4 cycles
Study: 11101062
Drug: scIL-2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: scIL-2 therapy plus antiretroviral therapy
Study: 11101062
Drug: antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiretroviral therapy alone (control group)
Study: 7813412
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) monotherapy
Study: 30345905
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus fulvestrant (among patients with sensitivity to previous endocrine therapy)
Study: 30345905
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus fulvestrant (among patients with sensitivity to previous endocrine therapy)
Study: 21745388
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (2 times per week for 12 sessions over 6 weeks)
Study: 21745388
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control (no acupuncture treatment for the first 6 weeks)